Compass Therapeutics Q2 2026 net loss widens 26.63% to $25.2 million; R&D expenses rise 19% to $19.6 million
CMPX•Cash position and outlook
Cash and marketable securities totaled $180 million at June 30, with management expecting funding into 2028 and FDA feedback in Q3 on tovecimig BTC data.
R&D and G&A costs increase
R&D expense rose 19% to $19.6 million, driven primarily by $2.6 million higher tovecimig-related spending.
G&A expense climbed 59% to $7.4 million on $1.4 million higher pre-commercialization costs and $0.8 million higher stock compensation.
Quarterly loss widens as expenses rise
Compass Therapeutics posted a Q2 net loss of $25.2 million, widening from $19.9 million a year earlier.
Loss per share was $0.13, improving from $0.14 in the prior-year quarter.
